SCHEMBL2438657

SCHEMBL2438657

CCOC(=O)c1c(O)c2ccc(C(F)(F)F)nc2n(C)c1=O

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.55
KDM4E B2RXH2 6/20 0.55
LMNA P02545 2/20 0.45
RECQL P46063 1/20 0.44
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPC1 O15118 1/20 0.41
ALOX15 P16050 1/20 0.41
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
PABPC1 P11940 1/20 0.39
KMT2A Q03164 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KDM5A P29375 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2086304 0.86 KDM4E (0.47) ALDH1A1KDM4ELMNARECQLHTT
SCHEMBL29305790 0.85 RECQL (0.49) ALDH1A1KDM4ELMNARECQLHTT
SCHEMBL27164069 0.85 RECQL (0.60) ALDH1A1KDM4ELMNARECQLSMN1; SMN2
SCHEMBL30049478 0.85 RECQL (0.60) ALDH1A1KDM4ELMNARECQLSMN1; SMN2
SCHEMBL8141322 0.84 ALDH1A1 (0.61) ALDH1A1KDM4ELMNARECQLHTT
SCHEMBL29305733 0.83 RECQL (0.47) ALDH1A1KDM4ELMNARECQLHTT
SCHEMBL8143270 0.83 ALDH1A1 (0.60) ALDH1A1KDM4ELMNARECQLHTT
SCHEMBL8137044 0.81 ALDH1A1 (0.57) ALDH1A1KDM4ELMNARECQLHTT
SCHEMBL2088734 0.81 KDM4E (0.44) ALDH1A1KDM4ELMNARECQLHTT
SCHEMBL336505 0.81 ALDH1A1 (0.51) ALDH1A1KDM4ELMNARECQLHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142509-B1 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC (US) 2013-12-04 EP disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
EP-2097416-B1 AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC (US) 2012-09-12 EP disclosed
EP-2097416-B1 AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC (US) 2012-09-12 EP disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-8048892-B2 Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-11-01 US disclosed
US-8048892-B2 Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-11-01 US disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
US-20090111806-A1 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-30 US disclosed
US-20090111806-A1 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-30 US disclosed
US-20090111806-A1 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-30 US disclosed
WO-2008130600-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO disclosed
WO-2008130600-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO disclosed
WO-2008076425-A1 AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2008-06-26 WO disclosed
WO-2008076425-A1 AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase EGLN3, HIF1AN, EGLN2 ALDH1A1 191/4885KDM4E 336/4885LMNA 2607/4885
US-20090111806-A1 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof EGLN3, EGLN2, HIF1AN ALDH1A1 678/4885KDM4E 99/4885LMNA 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.